Mouse PD-L1 / B7-H1 / CD274 Protein (His & Fc Tag)
A530045L16Rik,B7h1,Pdcd1l1,Pdcd1lg1,Pdl1
- 100ug (NPP1569) Please inquiry
| Catalog Number | P50010-M03H |
|---|---|
| Organism Species | Mouse |
| Host | Human Cells |
| Synonyms | A530045L16Rik,B7h1,Pdcd1l1,Pdcd1lg1,Pdl1 |
| Molecular Weight | The recombinant mouse PD-L1/Fc is a disulfide-linked homodimeric protein after proteolytic removal of the signal peptide. The reduced monomer consists of 468 amino acids and predicts a molecular mass of 52.8 kDa. As a result of glycosylation, the apparent molecular mass of rm PD-L1/Fc monomer is approximately 65-75 kDa in SDS-PAGE under reducing conditions. |
| predicted N | Phe 19 |
| SDS-PAGE |  |
| Purity | > 97 % as determined by SDS-PAGE |
| Protein Construction | A DNA sequence encoding the extracellular domain (Met 1-Thr 238) of mouse PD-L1 (NP_068693.1) was fused with the C-terminal His-tagged Fc region of human IgG1 at the C-terminus. |
| Bio-activity | Measured by its binding ability in a functional ELISA . Immobilized recombinant mouse PD-1 at 10 μg/ml (100 μl/well) can bind biotinylated mouse PD-L1 with a linear range of 3.2-400 ng/ml . |
| Research Area | Immunology |Innate Immunity |Monocytes/Macrophages |Macrophage Markers |
| Formulation | Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
| Background | Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. |
| Reference |